Results you can trust
For transformative diagnostic solutions, more healthcare institutions turn to Cepheid as their trusted diagnostic partner. Through proven scientific expertise and innovative test design, Cepheid now delivers the game-changing Xpert® HCV-the first-ever CLIA waived hepatitis C RNA test in the U.S. supporting a robust elimination plan for hepatitis C.
The Viral Hepatitis National Strategic Plan for the United States calls for greater than 80% of people with hepatitis C to achieve viral clearance by 20301. Currently, the diagnostic pathway for detection of hepatitis C faces many barriers, including complicated multi-step diagnostic algorithms based on antibody screening and RNA confirmation2. These algorithms require centralized testing technologies that may result in treatment delays and discourage at-risk populations from accessing testing and receiving care.
Transforming Patient Care
With Cepheid’s Xpert® HCV, patients can undergo testing, receive a diagnosis, and seamlessly connect to treatment and care in a single visit. This efficient process has the potential to save time and can ensure more patients stay in care, leading to more people cured of hepatitis C.
David H. Persing, M.D., Ph.D.
Cepheid's Chief Medical and Technology Officer
1
2
3
Cepheid’s CLIA waived Xpert® HCV test, authorized by the FDA, allows complete hepatitis C RNA testing at the point-of-care. The test runs on the Xpert® GeneXpert system, enabling any trained healthcare professional, regardless of skill level, to administer the test. This easy-to-use solution provides Lab in a Cartridge™ results when and where they are needed.
The Impact of Point of Care Hepatitis C Testing Globally